[Skip to Content]
[Skip to Content Landing]
Editorial
January 1, 2014

Vitamin E, Memantine, and Alzheimer Disease

Author Affiliations
  • 1Department of Internal Medicine, Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois
  • 2Department of Internal Medicine, Section of Nutrition and Nutritional Epidemiology, Rush University Medical Center, Chicago, Illinois
JAMA. 2014;311(1):29-30. doi:10.1001/jama.2013.282835

The report by Dysken et al1 in this issue of JAMA raises interesting issues about drug therapy for Alzheimer disease (AD) and emphasizes the importance of closely following this rapidly evolving field. In this randomized clinical trial, older veterans (97% men) with AD and Mini-Mental State Examination (MMSE) scores of 12 to 26 who were receiving acetylcholinesterase inhibitors were assigned to 1 of 4 treatment groups: receiving synthetic vitamin E (alpha tocopherol, 2000 IU/d); memantine, 20 mg/d; both agents; or placebo.

First Page Preview View Large
First page PDF preview
First page PDF preview
×